

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
18 May 2007 (18.05.2007)

PCT

(10) International Publication Number  
WO 2007/054215 A1(51) International Patent Classification:  
A61K 31/495 (2006.01) A61P 11/00 (2006.01)

(74) Common Representative: BAYER HEALTHCARE AG; Law and Patents, Patents and Licensing, 51368 Leverkusen (DE).

(21) International Application Number:  
PCT/EP2006/010405

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(22) International Filing Date: 30 October 2006 (30.10.2006)

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

(26) Publication Language: English

**Published:**

— with international search report

(30) Priority Data:  
05024508.3 10 November 2005 (10.11.2005) EP  
05027449.7 15 December 2005 (15.12.2005) EP  
06007775.7 13 April 2006 (13.04.2006) EP

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicant (for all designated States except US): BAYER HEALTHCARE AG [DE/DE]; 51368 Leverkusen (DE).

## (72) Inventors; and

(75) Inventors/Applicants (for US only): SANDNER, Peter [DE/DE]; Julius-Lucas-Weg 59, 42113 Wuppertal (DE). TINEL, Hanna [PL/DE]; Westfalenweg 14, 42111 Wuppertal (DE). HÜTTER, Joachim [DE/DE]; Teschensudberger Str. 13, 42349 Wuppertal (DE). RIEDL, Bernd [DE/DE]; Von-der-Goltz-Str. 7, 42329 Wuppertal (DE). KLEIN, Martina [DE/DE]; Wilhelmstr. 59, 42553 Velbert (DE).

WO 2007/054215 A1

(54) Title: DIARYL UREAS FOR TREATING PULMONARY HYPERTENSION

(57) Abstract: The present invention relates to pharmaceutical compositions for treating, preventing or managing pulmonary hypertension comprising at least a diaryl urea compound optionally combined with at least one additional therapeutic agent. Useful combinations include e.g. BAY 43-9006 as a diaryl urea compound.

**DIARYL UREAS FOR TREATING PULMONARY HYPERTENSION**

The present invention relates to pharmaceutical compositions for treating, preventing or managing pulmonary hypertension comprising at least a diaryl urea compound optionally combined with at least one additional therapeutic agent. Useful combinations include e.g. BAY 43-9006 as a diaryl urea compound.

BAY 43-9006 refers to 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-phenoxy}-pyridine-2-carboxylic acid methyl amide and is species of diaryl urea compounds which are potent anti-cancer and anti-angiogenic agents that possess various activities, including inhibitory activity on the VEGFR, PDGFR, raf, p38, and/or flt-3 kinase signaling molecules. See, e.g., WO 2004/113274

and WO 2005/000284.


Pulmonary hypertension refers to a disease characterized by sustained elevations of pulmonary artery pressure (L.J. Rubin, The New England Journal of Medicine, 1997, 336(2), 111). Current treatment of pulmonary hypertension depends on the stage and the mechanism of the disease. Typical treatments for pulmonary hypertension include anticoagulation, oxygen supplementation, conventional vasodilator therapy, transplantation and surgical care. Therapeutic agents presently used for the treatment of pulmonary hypertension include e.g. calcium channel blockers and pulmonary vasodilators

The present invention provides pharmaceutical compositions for treating, preventing or managing pulmonary hypertension comprising at least one compound of formula I and optionally at least one further therapeutic agent.

The present invention can be used e.g. by administering a diaryl urea compound of formula I and optionally a further therapeutic agent, pharmaceutically-acceptable salts thereof, and derivatives thereof, etc.

The compounds with the structure of formula (I), pharmaceutically acceptable salts, polymorphs, solvates, hydrates metabolites and prodrugs thereof, including diastereoisomeric forms (both isolated stereoisomers and mixtures of stereoisomers) are collectively referred to herein as the "compounds of formula I".

Formula (I) is as follows:



wherein

Q is  $-C(O)R_x$

$R_x$  is hydroxy,  $C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy or  $NR_aR_b$ ,

5  $R_a$  and  $R_b$  are independently :

a) hydrogen;

b)  $C_{1-4}$  alkyl, optionally substituted by

-hydroxy,

$-C_{1-4}$  alkoxy,

10 - a heteroaryl group selected from pyrrole, furan, thiophene, imidazole, pyrazole, thiazole, oxazole, isoxazole, isothiazole, triazole, tetrazole, thiadiazole, oxadiazole, pyridine, pyrimidine, pyridazine, pyrazine, triazine, benzoxazole, isoquiline, quinolines and imidazopyrimidine

15 - a heterocyclic group selected from tetrahydropyran, tetrahydrofuran, 1,3-dioxolane, 1,4-dioxane, morpholine, thiomorpholine, piperazine, piperidine, piperidinone, tetrahydropyrimidone, pentamethylene sulfide, tetramethylene sulfide, dihydropyran, dihydrofuran, and dihydrothiophene,

- amino,  $-NH_2$ , optionally substituted by one or two  $C_{1-4}$  alkyl groups, or

- phenyl,

20 c) phenyl optionally substituted with

- halogen, or

- amino,  $-NH_2$ , optionally substituted by one or two  $C_{1-4}$  alkyl, or

- 3 -

- d) - a heteroaryl group selected from pyrrole, furan, thiophene, imidazole, pyrazole, thiazole, oxazole, isoxazole, isothiazole, triazole, tetrazole, thiadiazole, oxadiazole, pyridine, pyrimidine, pyridazine, pyrazine, triazine, benzoxazole, isoquiline, quinoline and imidazopyrimidine;

5           A    is optionally substituted phenyl, pyridinyl, naphthyl, benzoxazole, isoquiline, quinoline or imidazopyrimidine;


          B    is optionally substituted phenyl or naphthyl;

          L    is a bridging group which is -S- or -O-;


          m    is 0,1,2 or 3, and

10          each R<sup>2</sup> is independently C<sub>1-5</sub> alkyl, C<sub>1-5</sub> haloalkyl, C<sub>1-3</sub> alkoxy, N-oxo or N-hydroxy.


Structures of optionally substituted phenyl moieties for A of formula (I) which are of particular interest include structures of formula 1xx:



15          Structures of optionally substituted pyridinyl moieties for A of formula (I) which are of particular interest include structures of formula 1x:




Structures of optionally substituted naphthyl moieties for A of formula (I) which are of particular interest include structures of formula 1y:



The structure 1y represents that the substituents  $R^3$  can appear on any carbon atom in either ring which has a valence that is otherwise complete with a hydrogen atom as a substituent. The bond to the urea group can also be through any carbon atom on either ring which has a valence that is otherwise complete with a hydrogen atom as a substituent.

5

B is optionally substituted phenyl or naphthyl. Structures of optionally substituted phenyl or naphthyl moieties for B of formula (I) which are of particular interest include structures 2a and 2b:



The structures 2a and 2b represent that the substituents  $R^1$  can appear on any carbon atom in the structure which has a valence that is otherwise complete with a hydrogen atom as a substituent and the bond to the urea group can be through any carbon atom in the structure which has a valence that is otherwise complete with a hydrogen atom as a substituent.

10

In a class of embodiments of this invention, B is substituted by at least one halogen substituent. In another class of embodiments,  $R_x$  is  $NR_aR_b$ , and  $R_a$  and  $R_b$  are independently hydrogen or  $C_{1-4}$  alkyl optionally substituted by hydroxy and L is a bridging group which is -S- or -O-.

15

The variable p is 0, 1, 2, 3, or 4, typically 0 or 1. The variable n is 0, 1, 2, 3, 4, 5 or 6, typically 0, 1, 2, 3 or 4. The variable m is 0, 1, 2 or 3, typically 0.

Each  $R^1$  is independently: halogen,  $C_{1-5}$  haloalkyl,  $NO_2$ ,  $C(O)NR^4R^5$ ,  $C_{1-6}$  alkyl,  $C_{1-6}$  dialkylamine,  $C_{1-3}$  alkylamine,  $CN$ , amino, hydroxy or  $C_{1-3}$  alkoxy. Where present,  $R^1$  is more commonly halogen and of the halogens, typically chlorine or fluorine, and more commonly fluorine.

20


Each  $R^2$  is independently:  $C_{1-5}$  alkyl,  $C_{1-5}$  haloalkyl,  $C_{1-3}$  alkoxy, N-oxo or N-hydroxy. Where present,  $R^2$  is typically methyl or trifluoromethyl.

Each  $R^3$  is independently selected from halogen,  $R^4$ ,  $OR^4$ ,  $S(O)R^4$ ,  $C(O)R^4$ ,  $C(O)NR^4R^5$ , oxo, cyano or nitro ( $NO_2$ ).

$R^4$  and  $R^5$  are independently selected from hydrogen,  $C_{1-6}$  alkyl, and up to per-halogenated  $C_{1-6}$  alkyl.

5 Other examples of A include: 3-tert butyl phenyl, 5-tert butyl-2-methoxyphenyl, 5-(trifluoromethyl)-2 phenyl, 3-(trifluoromethyl) -4 chlorophenyl, 3-(trifluoromethyl)-4-bromophenyl and 5-(trifluoromethyl)-4-chloro-2 methoxyphenyl.

Other examples of B include:




10 Preferably the urea group  $-NH-C(O)-NH-$  and the bridging group, L, are not bound to contiguous ring carbons of B, but rather have 1 or 2 ring carbons separating them.

Examples of  $R^1$  groups include fluorine, chlorine, bromine, methyl,  $NO_2$ ,  $C(O)NH_2$ , methoxy,  $SCH_3$ , trifluoromethyl, and methanesulfonyl.

Examples of  $R^2$  groups include methyl, ethyl, propyl, oxygen, and cyano.


15 Examples of  $R^3$  groups include trifluoromethyl, methyl, ethyl, propyl, butyl, isopropyl, tert-butyl, chlorine, fluorine, bromine, cyano, methoxy, acetyl, trifluoromethanesulfonyl, trifluoromethoxy, and trifluoromethylthio.



A class of compounds of interest are of formula II below


5 wherein Ra and Rb are independently hydrogen and C<sub>1</sub>-C<sub>4</sub> alkyl,

B of formula II is



wherein the urea group, -NH-C(O)-NH-, and the oxygen bridging group are not bound to contiguous ring carbons of B, but rather have 1 or 2 ring carbons separating them,

10 and A of formula (II) is




wherein the variable n is 0, 1, 2, 3 or 4.

$R^3$  is trifluoromethyl, methyl, ethyl, propyl, butyl, isopropyl, tert-butyl, chlorine, fluorine, bromine, cyano, methoxy, acetyl, trifluoromethanesulfonyl, trifluoromethoxy, or trifluoromethylthio.

In a subclass of such compounds, each  $R^3$  substituent on A of formula II is selected from chlorine, trifluoromethyl, tert-butyl or methoxy.


5      In another subclass of such compounds, A of formula II is



and B of formula II is phenylene, fluoro substituted phenylene or difluoro substituted phenylene.

Another class of compounds of interest includes compounds having the structure of formulae X

10      below wherein phenyl ring "B" optionally has one halogen substituent.





For the compounds of formula X,  $R^2$ , m and A are as defined above for formula I. The variable "m" is preferably zero, leaving  $C(O)NHCH_3$  as the only substituent on the pyridinyl moiety.

Preferred values for A are substituted phenyl which have at least one substituent,  $R^3$ .  $R^3$  is

15      preferably halogen, preferably Cl or F, trifluoromethyl and/or methoxy.

A subclass of compounds of interest includes compounds having the structure of formulas Z1 and

Z2 below :



Preferably used as compound of formula I according to the invention is 4{4-[3-(4-chloro-3-

5 trifluoromethylphenyl)-ureido]-phenoxy}-pyridine-2-carboxylic acid methyl amide (BAY 43-  
9006) or the *p*-toluenesulfonic acid salt of 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-  
10 phenoxy}-pyridine-2-carboxylic acid methyl amide (tosylate salt of compound (I)). More  
preferably the *p*-toluenesulfonic acid salt of 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-  
15 phenoxy}-pyridine-2-carboxylic acid methyl amide exists for at least 80% in the stable polymorph  
I. Most preferably the *p*-toluenesulfonic acid salt of 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-  
ureido]-phenoxy}-pyridine-2-carboxylic acid methyl amide exists for at least 80% in the stable  
20 polymorph I and in a micronized form.

Micronization can be achieved by standard milling methods, preferably by air chat milling, known  
15 to a skilled person. The micronized form can have a mean particle size of from 0.5 to 10  $\mu\text{m}$ ,  
preferably from 1 to 6  $\mu\text{m}$ , more preferably from 1 to 3  $\mu\text{m}$ . The indicated particle size is the mean  
20 of the particle size distribution measured by laser diffraction known to a skilled person (measuring  
device: HELOS, Sympatec).

The process for preparing the *p*-toluenesulfonic acid salt of 4{4-[3-(4-chloro-3-trifluoromethyl-  
phenyl)-ureido]-phenoxy}-pyridine-2-carboxylic acid methyl amide and its stable polymorph I are  
20 described in the patent applications EP 04023131.8 and EP 04023130.0.

When any moiety is “substituted”, it can have up to the highest number of indicated substituents  
and each substituent can be located at any available position on the moiety and can be attached  
through any available atom on the substituent. “Any available position” means any position on the  
moiety that is chemically accessible through means known in the art or taught herein and that does  
25 not create an unstable molecule, e.g., incapable of administration to a human. When there are two

or more substituents on any moiety, each substituent is defined independently of any other substituent and can, accordingly, be the same or different.

The term "optionally substituted" means that the moiety so modified may be either unsubstituted, or substituted with the identified substituent(s).

5 It is understood that the term "hydroxy" as a pyridine substituent includes 2-, 3-, and 4-hydroxypyridine, and also includes those structures referred to in the art as 1-oxo-pyridine, 1-hydroxy-pyridine or pyridine N-oxide.

Where the plural form of the word compounds, salts, and the like, is used herein, this is taken to mean also a single compound, salt, or the like.

10 The term  $C_{1-6}$  alkyl, unless indicated otherwise, means straight, branched chain or cyclic alkyl groups having from one to six carbon atoms, which may be cyclic, linear or branched with single or multiple branching. Such groups include for example methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, cyclopropyl, cyclobutyl and the like.

15 The term  $C_{1-6}$  haloalkyl, unless indicated otherwise, means a saturated hydrocarbon radical having up to six carbon atoms, which is substituted with at least one halogen atom, up to perhalo. The radical may be cyclic, linear or branched with single or multiple branching. The halo substituent(s) include fluoro, chloro, bromo, or iodo. Fluoro, chloro and bromo are preferred, and fluoro and chloro are more preferred. The halogen substituent(s) can be located on any available carbon. When more than one halogen substituent is present on this moiety, they may be the same or different. Examples of such halogenated alkyl substituents include but are not limited to chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, and 1,1,2,2-tetrafluoroethyl, and the like.

20 The term  $C_{1-6}$  alkoxy, unless indicated otherwise, means a cyclic, straight or branched chain alkoxy group having from one to six saturated carbon atoms which may be cyclic, linear or branched with single or multiple branching, and includes such groups as methoxy, ethoxy, *n*-propoxy, isopropoxy, butoxy, pentoxy and the like. It also includes halogenated groups such as 2,2-dichloroethoxy, trifluoromethoxy, and the like.

Halo or halogen means fluoro, chloro, bromo, or iodo. Fluoro, chloro and bromo are preferred, and fluoro and chloro are more preferred.

30  $C_{1-3}$ alkylamine, unless indicated otherwise, means methylamino, ethylamino, propylamino or isopropylamino.

Examples of C<sub>1-6</sub> dialkylamine include but are not limited to diethylamino, ethyl-isopropylamino, methyl-isobutylamino and dihexylamino.

The term heteroaryl refers to both monocyclic and bicyclic heteroaryl rings. Monocyclic heteroaryl means an aromatic monocyclic ring having 5 to 6 ring atoms and 1-4 hetero atoms selected from N, O and S, the remaining atoms being carbon. When more than one hetero atom is present in the moiety, they are selected independently from the other(s) so that they may be the same or different.

5 Monocyclic heteroaryl rings include, but are not limited to pyrrole, furan, thiophene, imidazole, pyrazole, thiazole, oxazole, isoxazole, isothiazole, triazole, tetrazole, thiadiazole, oxadiazole, pyridine, pyrimidine, pyridazine, pyrazine, and triazine.

10 Bicyclic heteroaryl means fused bicyclic moieties where one of the rings is chosen from the monocyclic heteroaryl rings described above and the second ring is either benzene or another monocyclic heteroaryl ring described above. When both rings in the bicyclic moiety are heteroaryl rings, they may be the same or different, as long as they are chemically accessible by means known in the art. Bicyclic heteroaryl rings include synthetically accessible 5-5, 5-6, or 6-6 fused bicyclic 15 aromatic structures including, for example but not by way of limitation, benzoxazole (fused phenyl and oxazole), quinoline (fused phenyl and pyridine), imidazopyrimidine (fused imidazole and pyrimidine), and the like.

Where indicated, the bicyclic heteroaryl moieties may be partially saturated. When partially saturated either the monocyclic heteroaryl ring as described above is fully or partially saturated, 20 the second ring as described above is either fully or partially saturated or both rings are partially saturated.

The term "heterocyclic group", unless indicated otherwise, means monocyclic and bicyclic moieties containing at least one atom selected from oxygen, nitrogen and sulfur, which is saturated or partially saturated, and includes, by no way of limitation, tetrahydropyran, tetrahydrofuran, 1,3-25 dioxolane, 1,4-dioxane, morpholine, thiomorpholine, piperazine, piperidine, piperidinone, tetrahydropyrimidone, pentamethylene sulfide, tetramethylene sulfide, dihydropyran, dihydrofuran, dihydrothiophene and the like.

The term "C<sub>1-3</sub> alkyl-phenyl" includes, for example, 2-methylphenyl, isopropylphenyl, 3-phenylpropyl, or 2-phenyl-1-methylethyl. Substituted examples include 2-[2-chlorophenyl]ethyl, 30 3,4-dimethylphenylmethyl, and the like.

Unless otherwise stated or indicated, the term "aryl" includes 6-12 membered mono or bicyclic aromatic hydrocarbon groups (e.g., phenyl, naphthalene, azulene, indene group) having 0, 1, 2, 3, 4, 5 or 6 substituents.

The compounds of formula (I) may contain one or more asymmetric centers, depending upon the 5 location and nature of the various substituents desired. Asymmetric carbon atoms may be present in the (R) or (S) configuration or (R,S) configuration. In certain instances, asymmetry may also be present due to restricted rotation about a given bond, for example, the central bond adjoining two substituted aromatic rings of the specified compounds. Substituents on a ring may also be present 10 in either cis or trans form. It is intended that all such configurations (including enantiomers and diastereomers), are included within the scope of the present invention. Preferred compounds are 15 those with the absolute configuration of the compound of formula (I) which produces the more desirable biological activity. Separated, pure or partially purified isomers or racemic mixtures of the compounds of this invention are also included within the scope of the present invention. The purification of said isomers and the separation of said isomeric mixtures can be accomplished by standard techniques known in the art.

The optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, for example, by the formation of diastereoisomeric salts using an optically active acid or base or formation of covalent diastereomers. Examples of appropriate acids are tartaric, diacetyl tartaric, ditoluoyl tartaric and camphorsulfonic acid. Mixtures of diastereoisomers 20 can be separated into their individual diastereomers on the basis of their physical and/or chemical differences by methods known in the art, for example, by chromatography or fractional crystallization. The optically active bases or acids are then liberated from the separated diastereomeric salts. A different process for separation of optical isomers involves the use of chiral chromatography 25 (e.g., chiral HPLC columns), with or without conventional derivation, optimally chosen to maximize the separation of the enantiomers. Suitable chiral HPLC columns are manufactured by Diacel, e.g., Chiracel OD and Chiracel OJ among many others, all routinely selectable. Enzymatic separations, with or without derivitization, are also useful. The optically active compounds of formula I can likewise be obtained by chiral syntheses utilizing optically active starting materials.

The present invention also relates to useful forms of the compounds as disclosed herein, such as 30 pharmaceutically acceptable salts, metabolites and prodrugs. The term "pharmaceutically acceptable salt" refers to a relatively non-toxic, inorganic or organic acid addition salt of a compound of the present invention. For example, see S. M. Berge, *et al.* "Pharmaceutical Salts," *J. Pharm. Sci.* 1977, 66, 1-19. Pharmaceutically acceptable salts include those obtained by reacting the main compound, functioning as a base, with an inorganic or organic acid to form a salt, for

example, salts of hydrochloric acid, sulfuric acid, phosphoric acid, methane sulfonic acid, camphor sulfonic acid, oxalic acid, maleic acid, succinic acid and citric acid. Pharmaceutically acceptable salts also include those in which the main compound functions as an acid and is reacted with an appropriate base to form, e.g., sodium, potassium, calcium, magnesium, ammonium, and choline salts. Those skilled in the art will further recognize that acid addition salts of the claimed compounds may be prepared by reaction of the compounds with the appropriate inorganic or organic acid via any of a number of known methods. Alternatively, alkali and alkaline earth metal salts are prepared by reacting the compounds of the invention with the appropriate base via a variety of known methods.

10 Representative salts of the compounds of this invention include the conventional non-toxic salts and the quaternary ammonium salts which are formed, for example, from inorganic or organic acids or bases by means well known in the art. For example, such acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cinnamate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, itaconate, lactate, maleate, mandelate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, sulfonate, tartrate, thiocyanate, tosylate, trifluoromethanesulfonate, and undecanoate.

15

20 Base salts include alkali metal salts such as potassium and sodium salts, alkaline earth metal salts such as calcium and magnesium salts, and ammonium salts with organic bases such as dicyclohexylamine and N-methyl-D-glucamine. Additionally, basic nitrogen containing groups may be quaternized with such agents as lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, and dibutyl sulfate; and

25 diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aryl or aralkyl halides like benzyl and phenethyl bromides and others monosubstituted aralkyl halides or polysubstituted aralkyl halides.

30 Solvates for the purposes of the invention are those forms of the compounds where solvent molecules form a complex in the solid state and include, but are not limited to for example ethanol and methanol. Hydrates are a specific form of solvates, where the solvent molecule is water.

Certain pharmacologically active agents can be further modified with labile functional groups that are cleaved after *in vivo* administration to furnish the parent active agent and the pharmacologically inactive derivatizing group. These derivatives, commonly referred to as prodrugs, can be used, for example, to alter the physicochemical properties of the active agent, to target the

active agent to a specific tissue, to alter the pharmacokinetic and pharmacodynamic properties of the active agent, and to reduce undesirable side effects. Prodrugs of the invention include, e.g., the esters of appropriate compounds of this invention that are well-tolerated, pharmaceutically acceptable esters such as alkyl esters including methyl, ethyl, propyl, isopropyl, butyl, isobutyl or 5 pentyl esters. Additional esters such as phenyl-C<sub>1</sub>-C<sub>5</sub> alkyl may be used, although methyl ester is preferred.

Methods which can be used to synthesize other prodrugs are described in the following reviews on the subject, which are incorporated herein by reference for their description of these synthesis methods:

10 • Higuchi, T.; Stella, V. eds. *Prodrugs As Novel Drug Delivery Systems*. ACS Symposium Series. American Chemical Society: Washington, DC (1975).

• Roche, E. B. *Design of Biopharmaceutical Properties through Prodrugs and Analogs*. American Pharmaceutical Association: Washington, DC (1977).

• Sinkula, A. A.; Yalkowsky, S. H. *J Pharm Sci*. **1975**, *64*, 181-210.

15 • Stella, V. J.; Charman, W. N. Naringrekar, V. H. *Drugs* **1985**, *29*, 455-473.

• Bundgaard, H., ed. *Design of Prodrugs*. Elsevier: New York (1985).

• Stella, V. J.; Himmelstein, K. J. *J. Med. Chem.* **1980**, *23*, 1275-1282.

• Han, H-K; Amidon, G. L. *AAPS Pharmsci* **2000**, *2*, 1- 11.

• Denny, W. A. *Eur. J. Med. Chem.* **2001**, *36*, 577-595.

20 • Wermuth, C. G. in Wermuth, C. G. ed. *The Practice of Medicinal Chemistry* Academic Press: San Diego (1996), 697-715.

• Balant, L. P.; Doelker, E. in Wolff, M. E. ed. *Burgers Medicinal Chemistry And Drug Discovery* John Wiley & Sons: New York (1997), 949-982.

25 The metabolites of the compounds of this invention include oxidized derivatives of the compounds of formula I, II, X, Z1 and Z2, wherein one or more of the nitrogens are substituted with a hydroxy group; which includes derivatives where the nitrogen atom of the pyridine group is in the oxide form, referred to in the art as 1-oxo-pyridine or has a hydroxy substituent, referred to in the art as 1-hydroxy-pyridine.

### General Preparative Methods

The particular process to be utilized in the preparation of the compounds used in this embodiment of the invention depends upon the specific compound desired. Such factors as the selection of the specific substituents play a role in the path to be followed in the preparation of the specific 5 compounds of this invention. Those factors are readily recognized by one of ordinary skill in the art.

The compounds of the invention may be prepared by use of known chemical reactions and procedures as described in the following published international applications WO 00/42012, WO03/047579, WO 2005/009961, WO 2004/078747 and WO05/000284 and European patent 10 applications EP 04023131.8 and EP 04023130.0.

The compounds of the invention can be made according to conventional chemical methods, and/or as disclosed below, from starting materials which are either commercially available or producible according to routine, conventional chemical methods. General methods for the preparation of the compounds are given below.

15 The preparation of ureas of formula (I) can be prepared from the condensation of the two arylamine fragments and in the presence of phosgene, di-phosgene, tri-phosgene, carbonyldi-imidazole, or equivalents in a solvent that does not react with any of the starting materials, as described in one or more of these published. Alternatively, compounds of formula (I) can be synthesized by reacting amino compounds) with isocyanate compounds as described in one or 20 more of the published international applications described above.

The isocyanates are commercially available or can be synthesized from heterocyclic amines according to methods commonly known to those skilled in the art [e.g. from treatment of an amine with phosgene or a phosgene equivalent such as trichloromethyl chloroformate (diphosgene), bis(trichloromethyl)carbonate (triphosgene), or *N,N*'-carbonyldiimidazole (CDI); or, alternatively 25 by a Curtius-type rearrangement of an amide, or a carboxylic acid derivative, such as an ester, an acid halide or an anhydride].

Aryl amines of formulas are commercially available, or can be synthesized according to methods commonly known to those skilled in the art. Aryl amines are commonly synthesized by reduction of nitroaryls using a metal catalyst, such as Ni, Pd, or Pt, and H<sub>2</sub> or a hydride transfer agent, such 30 as formate, cyclohexadiene, or a borohydride (Rylander. *Hydrogenation Methods*; Academic Press: London, UK (1985)). Nitroaryls may also be directly reduced using a strong hydride source, such as LiAlH<sub>4</sub> (Seydel-Penne. *Reductions by the Alumino- and borohydrides in Organic*

5 *Synthesis*; VCH Publishers: New York (1991)), or using a zero valent metal, such as Fe, Sn or Ca, often in acidic media. Many methods exist for the synthesis of nitroaryls (March. *Advanced Organic Chemistry*, 3<sup>rd</sup> Ed.; John Wiley: New York (1985). Larock. *Comprehensive Organic Transformations*; VCH Publishers: New York (1989)). Nitro aryls are commonly formed by electrophilic aromatic nitration using HNO<sub>3</sub>, or an alternative NO<sub>2</sub><sup>+</sup> source.

Pyridine-1-oxides of formula (I) where the pyridine ring carries a hydroxy substituent on its nitrogen atom, and A, B, L are broadly defined as above can be prepared from the corresponding pyridines using oxidation conditions known in the art. Some examples are as follows:

- peracids such as meta chloroperbenzoic acids in chlorinated solvents such as dichloromethane, dichloroethane, or chloroform (Markgraf et al., *Tetrahedron* 1991, 47, 183);
- (Me<sub>3</sub>SiO)<sub>2</sub> in the presence of a catalytic amount of perrhenic acid in chlorinated solvents such as dichloromethane (Coperet et al., *Tetrahedron Lett.* 1998, 39, 761);
- Perfluoro-cis-2-butyl-3-propyloxaziridine in several combinations of halogenated solvents (Amone et al., *Tetrahedron* 1998, 54, 7831);
- 15 • Hypofluoric acid - acetonitrile complex in chloroform (Dayan et al., *Synthesis* 1999, 1427);
- Oxone, in the presence of a base such as KOH, in water (Robker et al., *J. Chem. Res., Synop.* 1993, 10, 412);
- Magnesium monoperoxyphthalate, in the presence of glacial acetic acid (Klemm et al., *J. Heterocyclic Chem.* 1990, 6, 1537);
- 20 • Hydrogen peroxide, in the presence of water and acetic acid (Lin A.J., *Org. Prep. Proced. Int.* 1991, 23(1), 114);
- Dimethyldioxirane in acetone (Boyd et al., *J. Chem. Soc., Perkin Trans.* 1991, 9, 2189).

In addition, specific methods for preparing diaryl ureas and intermediate compounds are already described elsewhere in the patent literature, and can be adapted to the compounds of the present invention. For example, Miller S. et al., "Inhibition of p38 Kinase using Symmetrical and Unsymmetrical Diphenyl Ureas" *PCT Int. Appl.* WO 99 32463, Miller, S et al. "Inhibition of raf Kinase using Symmetrical and Unsymmetrical Substituted Diphenyl Ureas" *PCT Int. Appl.*, WO 99 32436, Dumas, J. et al., "Inhibition of p38 Kinase Activity using Substituted Heterocyclic Ureas" *PCT Int. Appl.*, WO 99 32111, Dumas, J. et al., "Method for the Treatment of Neoplasm by 25 Inhibition of raf Kinase using N-Heteroaryl-N<sup>o</sup>-(hetero)arylureas" *PCT Int. Appl.*, WO 99 32106, 30

Dumas, J. et al., "Inhibition of p38 Kinase Activity using Aryl- and Heteroaryl- Substituted Heterocyclic Ureas" *PCT Int. Appl.*, WO 99 32110, Dumas, J., et al., "Inhibition of raf Kinase using Aryl- and Heteroaryl- Substituted Heterocyclic Ureas" *PCT Int. Appl.*, WO 99 32455, Riedl, B., et al., "O-Carboxy Aryl Substituted Diphenyl Ureas as raf Kinase Inhibitors" *PCT Int. Appl.*, 5 WO 00 42012, Riedl, B., et al., "O-Carboxy Aryl Substituted Diphenyl Ureas as p38 Kinase Inhibitors" *PCT Int. Appl.*, WO 00 41698, Dumas, J. et al. "Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors" *U.S. Pat. Appl. Publ.*, US 20020065296, Dumas, J. et al. "Preparation of N-aryl-N'-(acylphenoxy) phenyl]ureas as raf kinase inhibitors" *PCT Int. Appl.*, 10 WO 02 62763, Dumas, J. et al. "Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas" *PCT Int. Appl.*, WO 02 85857, Dumas, J. et al. "Preparation of quinolyl, isoquinolyl or pyridyl-ureas as inhibitors of raf kinase for the treatment of tumors and/or cancerous cell growth" *U.S. Pat. Appl. Publ.*, US 20020165394. All the preceding patent applications are hereby incorporated by reference.

Synthetic transformations that may be employed in the synthesis of compounds of formula (I) and 15 in the synthesis of intermediates involved in the synthesis of compounds of formula (I) are known by or accessible to one skilled in the art. Collections of synthetic transformations may be found in compilations, such as:

- J. March. *Advanced Organic Chemistry*, 4<sup>th</sup> ed.; John Wiley: New York (1992);
- R.C. Larock. *Comprehensive Organic Transformations*, 2<sup>nd</sup> ed.; Wiley-VCH: New York 20 (1999);
- F.A. Carey; R.J. Sundberg. *Advanced Organic Chemistry*, 2<sup>nd</sup> ed.; Plenum Press: New York (1984);
- T.W. Greene; P.G.M. Wuts. *Protective Groups in Organic Synthesis*, 3<sup>rd</sup> ed.; John Wiley: New York (1999);
- 25 • L.S. Hegedus. *Transition Metals in the Synthesis of Complex Organic Molecules*, 2<sup>nd</sup> ed.; University Science Books: Mill Valley, CA (1994);
- L.A. Paquette, Ed. *The Encyclopedia of Reagents for Organic Synthesis*; John Wiley: New York (1994);
- 30 • A.R. Katritzky; O. Meth-Cohn; C.W. Rees, Eds. *Comprehensive Organic Functional Group Transformations*; Pergamon Press: Oxford, UK (1995);

- G. Wilkinson; F.G A. Stone; E.W. Abel, Eds. *Comprehensive Organometallic Chemistry*; Pergamon Press: Oxford, UK (1982);
- B.M. Trost; I. Fleming. *Comprehensive Organic Synthesis*; Pergamon Press: Oxford, UK (1991);
- 5 • A.R. Katritzky; C.W. Rees Eds. *Comprehensive Heterocyclic Chemistry*; Pergamon Press: Oxford, UK (1984);
- A.R. Katritzky; C.W. Rees; E.F.V. Scriven, Eds. *Comprehensive Heterocyclic Chemistry II*; Pergamon Press: Oxford, UK (1996); and
- C. Hansch; P.G. Sammes; J.B. Taylor, Eds. *Comprehensive Medicinal Chemistry*; Pergamon 10 Press: Oxford, UK (1990).

In addition, recurring reviews of synthetic methodology and related topics include *Organic Reactions*; John Wiley: New York; *Organic Syntheses*; John Wiley: New York; *Reagents for Organic Synthesis*; John Wiley: New York; *The Total Synthesis of Natural Products*; John Wiley: New York; *The Organic Chemistry of Drug Synthesis*; John Wiley: New York; *Annual Reports in Organic Synthesis*; Academic Press: San Diego CA; and *Methoden der Organischen Chemie* (Houben-Weyl); Thieme: Stuttgart, Germany. Furthermore, databases of synthetic transformations include *Chemical Abstracts*, which may be searched using either CAS OnLine or SciFinder, *Handbuch der Organischen Chemie* (Beilstein), which may be searched using SpotFire, and REACCS.

## 20 **Further therapeutic agents**

The compounds of formula I according to the present invention can be combined with further therapeutic agents presently used to treat, prevent or manage pulmonary hypertension such as, but not limited to, anticoagulants, diuretics, cardiac glycosides, calcium channel blockers, vasodilators, prostacyclin analogues, endothelium antagonists, phosphodiesterase inhibitors, endopeptidase 25 inhibitors, lipid lowering agents, thromboxane inhibitors and other therapeutics known to reduce pulmonary artery pressure.

Examples of anticoagulants include, but are not limited to, e.g. warfarin useful in the treatment of patients with pulmonary hypertension having an increased risk of thrombosis and thromboembolism.

Examples of calcium channel blockers include, but are not limited to, diltiazem, felodipine, amlodipine and nifedipine particularly useful for vasoreactive patients at right heart catheterization.

5 Examples of vasodilators include, but are not limited to, e.g. prostacyclin, epoprostenol, treprostинil, nitric oxide (NO).

Examples of phosphodiesterase inhibitors include, but are not limited to, particularly phosphodiesterase V inhibitors such as e.g. tadalafil, sildenafil and vardenafil.

Examples of endothelin antagonists include, but are not limited to, e.g. bosentan and sitaxentan, preferably bosetan.

10 Examples of prostacyclin analogues include, but are not limited to, e.g. ilomedin, treprostинil and epoprostenol.

Examples of lipid lowering agents include, but are not limited to, e.g. HMG CoA reductase inhibitors such as simvastatin, pravastatin, atorvastatin, lovastatin, itavastatin, fluvastatin, pitavastatin, rosuvastatin, ZD-4522 and cerivastatin

15 Examples diuretics include, but are not limited to, e.g. chlorthalidon, indapamid, bendroflumethiazid, metolazon, cyclopenthiazid, polythiazid, mefrusid, ximapid, chlorothiazid and hydrochlorothiazid particularly useful to manage peripheral edema.

20 Examples of other therapeutics known to reduce pulmonary artery pressure include, but are not limited to, e.g. ACE inhibitors such as enalapril, ramipril, captopril, cilazapril, trandolapril, fosinopril, quinapril, moexipril, lisinopril and perindopril, or AT II inhibitors such as losartan, candesartan, irbesartan, embusartan, valsartan and telmisartan, or iloprost, betaprost, L-arginine, omapatrilat, oxygen particularly useful in those patients with resting or exercise-induced hypoxemia or digoxin particularly useful to improve right ventricular function in patients with right ventricular failure.

25 In addition the compounds and combinations of the invention can furthermore be combined with kinase inhibitors and/or elastase inhibitors.

30 Examples of kinase inhibitors include, but are not limited to, e.g. BMS-354825, canertinib, erlotinib, gefitinib, imatinib, lapatinib, lestaurtinib, lonafarnib, pegaptanib, pelitinib, semaxanib, tandutinib, tipifarnib, vatalanib, lonidamine, fasudil, leflunomide, bortezomib, imatinib, erlotinib and glivec. Preference is given to glivec.

### Indications

The compounds and combinations according to the present invention can be used for manufacture of a medicament for treating, preventing and managing pulmonary hypertension. Also the present invention provides methods of treating, preventing and managing pulmonary hypertension,

5 comprising administering effective amounts of at least one compound of formula I and optionally at least one further therapeutic agent according to the invention. An "effective amount" is the quantity of the compound that is useful to achieve the desired result, e.g., to treat, prevent or manage the disease or condition.

The term "pulmonary hypertension" according to the invention include, but is not limited to,

10 primary pulmonary hypertension, secondary pulmonary hypertension, familial pulmonary hypertension, sporadic pulmonary hypertension, precapillary pulmonary hypertension, pulmonary arterial, pulmonary artery hypertension, idiopathic pulmonary hypertension, thrombotic pulmonary arteriopathy, plexogenic pulmonary arteriopathy and pulmonary hypertension associated with or related to, left ventricular dysfunction, mitral valvular disease, constrictive pericarditis, aortic

15 stenosis, cardiomyopathy, mediastinal fibrosis, anomalous pulmonary venous drainage, pulmonary venoocclusive disease, collagen vascular disease, congenital heart disease, congenital heart disease, pulmonary venous hypertension, chronic obstructive pulmonary disease, interstitial lung disease, sleep-disordered breathing, alveolar hyperventilation disorder, chronic exposure to high altitude, neonatal lung disease, alveolar-capillary dysplasia, sickle cell disease, other coagulation

20 disorders, chronic thromboemboli, connective tissue disease, lupus, schistosomiasis, sarcoidosis or pulmonary capillary hemangiomatosis.

Any form of pulmonary hypertension can be treated in accordance with the present invention, including, but not limited to, mild, e.g., associated with increases of mean blood pressure of about 20-30 mm Hg at rest; moderate, e.g., associated with increases of 30-39 mm Hg at rest; and severe,

25 e.g., associated with increases of 40 mm Hg or more at rest.

Pulmonary hypertension includes pulmonary arterial hypertension (PAH), and includes, primary pulmonary hypertension (PPH), idiopathic PAH (IPAH), familial PAH (FPAH). Several classification systems for pulmonary hypertension have been published, including the Evian Nomenclature and Classification of pulmonary hypertension (PH) (1998) and the Revised

30 Nomenclature and Classification of PH (2003). See, Lewis et al., *Chest*, 2004, 126, 73-10, which is hereby incorporated by reference in its entirety. Any disease PH listed in these classification schemes can be treated, managed, or prevented in accordance with the present invention. Risk factors and diagnostic criteria for PH are described in McGoon et al., *Chest*, 126, 14-34, 2004, which is hereby incorporated by reference in its entirety.

The following list is the 2003 classification proposed at the Third World Conference on Pulmonary Hypertension: PAH, IPAH, FPAH, collagen vascular disease, congenital systemic to pulmonary shunts (large, small, repaired or nonrepaired), Portal hypertension, drugs and toxins, other (glycogen storage disease, gaucher disease, hereditary hemorrhagic telangiectasia,

5 hemoglobinopathies, myeloproliferative disorders, splenectomy), associated with significant venous or capillary involvement, pulmonary venous hypertension, pulmonary capillary hemangiomatosis, pulmonary venous hypertension, left-sided atrial ventricular heart disease, left-sided valvular heart disease, pulmonary hypertension associated with hypoxemia, COPD, interstitial lung disease, sleep-disordered breathing, alveolar hypoventilation disorders, chronic 10 exposure to high altitude, PH due to chronic thrombotic and/or embolic disease, thromboembolic obstruction of proximal pulmonary arteries, thromboembolic obstruction of distal pulmonary arteries, pulmonary embolism (tumor, parasites, foreign material), sarcoidosis, histiocytosis X, lymphangiomatosis, compression of pulmonary vessels (adenopathy, tumor, fibrosing mediastinitis)

15 Any of the above-mentioned disorders can be associated with an increased risk of pulmonary hypertension, including, subjects having, e.g., congenital heart disease (e.g., Eisenmenger syndrome); left heart disease; pulmonary venous disease (e.g., fibrosis tissue narrowing or occluding pulmonary veins and venules); pulmonary arterial disease; diseases causing alveolar hypoxia; fibrotic lung diseases; Williams syndrome; subjects with intravenous drug abuse injury; 20 pulmonary vasculitis (such as Wegener's, Goodpasture's, and Churg-Strauss syndromes); emphysema; chronic bronchitis; kyphoscoliosis; cystic fibrosis; obesity-hyper-ventilation and sleep apnea disorders; pulmonary fibrosis; sarcoidosis; silicosis; CREST (calcinosis cutis, Raynaud phenomenon; esophageal motility disorder; sclerodactyly, and telangiectasia) and other connective tissue diseases. For example, a subject who possesses a BMP2 mutation (bone 25 morphogenetic protein receptor II) has a 10-20% lifetime risk of acquiring FPAH. Subjects with hereditary hemorrhagic telangiectasia were also identified as being at risk for IPAH, especially those carrying mutations in ALK1. See, McGoon et al., *Chest*, 2004, 126, 14-34.

According to the invention the term "treating" refers to the administration of a pharmaceutical composition after the onset of symptoms of pulmonary hypertension, whereas "preventing" refers 30 to the administration prior to the onset of symptoms, particularly to patients at risk of pulmonary hypertension. The term "managing" encompasses preventing the recurrence of pulmonary hypertension in a patient who suffered from pulmonary hypertension.

## Administration

Compounds or drug combinations of the present invention can be administered in any form by any effective route, including, e.g., oral, parenteral, enteral, intravenous, intraperitoneal, topical, transdermal (e.g., using any standard patch), ophthalmic, nasally, local, non-oral, such as aerosol, 5 inhalation, subcutaneous, intramuscular, buccal, sublingual, rectal, vaginal, intra-arterial, and intrathecal, etc. They can be administered alone, or in combination with any ingredient(s), active or inactive.

Preference is given to an oral administration.

Compounds or drug combinations of the present invention can be converted in a known manner 10 into the usual formulations, which may be liquid or solid formulations e.g. without limitation normal and enteric coated tablets, capsules, pills, powders, granules, elixirs, tinctures, solution, suspensions, syrups, solid and liquid aerosols and emulsions.

Examples of solid formulations for oral administration are described in US provisional application Nos. 60/605,753 and 60/658,827.

15 The combinations of the present invention can be administered at any time and in any effective form. For example, the compounds can be administered simultaneously, e.g., as a single composition or dosage unit (e.g., a pill or liquid containing both compositions), or they can be administered as separate compositions, but at the same time (e.g., where one drug is administered intravenously and the other is administered orally or intramuscularly). The drugs can also be 20 administered sequentially at different times. Agents can be formulated conventionally to achieve the desired rates of release over extended period of times, e.g., 12-hours, 24-hours. This can be achieved by using agents and/or their derivatives which have suitable metabolic half-lives, and/or by using controlled release formulations.

25 The drug combinations can be synergistic, e.g., where the joint action of the drugs is such that the combined effect is greater than the algebraic sum of their individual effects. Thus, reduced amounts of the drugs can be administered, e.g., reducing toxicity or other deleterious or unwanted effects, and/or using the same amounts as used when the agents are administered alone, but achieving greater efficacy.

30 Compounds or drug combinations of the present invention can be further combined with any other suitable additive or pharmaceutically acceptable carrier. Such additives include any of the substances already mentioned, as well as any of those used conventionally, such as those described in Remington: The Science and Practice of Pharmacy (Gennaro and Gennaro, eds, 20th edition,

Lippincott Williams & Wilkins, 2000); Theory and Practice of Industrial Pharmacy (Lachman et al., eds., 3rd edition, Lippincott Williams & Wilkins, 1986); Encyclopedia of Pharmaceutical Technology (Swarbrick and Boylan, eds., 2nd edition, Marcel Dekker, 2002). These can be referred to herein as “pharmaceutically acceptable carriers” to indicate they are combined with the active drug and can be administered safely to a subject for therapeutic purposes.

In addition, compounds or drug combinations of the present invention can be administered with other active agents or other therapies that are utilized to treat any of the above-mentioned diseases and/or conditions.

Other therapies according to the invention include, but are not limited to, e.g. surgery such as arterial septostomy and lung transplantation therapy. Arterial septostomy and lung transplantation therapy may be necessary for pulmonary hypertension patients who failed to respond to medicinal therapy.

The present invention provides also combinations of at least one compound of Formula I and at least one other therapeutic agent mentioned above useful in treating a disease or disorder. “Combinations” for the purposes of the invention include:

- single compositions or dosage forms which contain at least one compound of Formula I and at least one other therapeutic agent mentioned above;
- combination packs containing at least one compound of Formula I and at least one other therapeutic agent mentioned above to be administered concurrently or sequentially;
- 20 -kits which comprise at least one compound of Formula I and at least one other therapeutic agent mentioned above packaged separate from one another as unit dosages or as independent unit dosages, with or without instructions that they be administered concurrently or sequentially; and
- separate independent dosage forms of at least one compound of Formula I and at least one other therapeutic agent mentioned above which cooperate to achieve a therapeutic effect, e.g., treatment of the same disease, when administered concurrently or sequentially.

The dosage of each agent of the combination can be selected with reference to the other and/or the type of disease and/or the disease status in order to provide the desired therapeutic activity. For example, the active agents in the combination can be present and administered in a fixed combination. “Fixed combination” is intended here to mean pharmaceutical forms in which the components are present in a fixed ratio that provides the desired efficacy. These amounts can be

determined routinely for a particular patient, where various parameters are utilized to select the appropriate dosage (e.g., type of disease, age of patient, disease status, patient health, weight, etc.), or the amounts can be relatively standard.

5 The amount of the administered active ingredient can vary widely according to such considerations as the particular compound and dosage unit employed, the mode and time of administration, the period of treatment, the age, sex, and general condition of the patient treated, the nature and extent of the condition treated, the rate of drug metabolism and excretion, the potential drug combinations and drug-drug interactions, and the like.

10 Preference is given to an amount of the compound of formula I from 20 to 2000 mg, preferably from 40 to 800 mg, more preferably from 50 to 600 mg.

Particular preference is given to an amount of p-toluenesulfonic acid salt of 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-phenoxy}-pyridine-2-carboxylic acid methyl amide in the pharmaceutical composition from 27 to 2740 mg, preferably from 54 to 1096, more preferably from 68 to 822 mg.

15 In another embodiment of the invention the compound of formula I is administered in combination with at least one further therapeutic agent in an amount that those of ordinary skill in the art can determine by their professional judgement.

20 The pharmaceutical composition according to the invention is administered one or more, preferably up to three, more preferably up to two times per day. Preference is given to an administration via the oral route. With each administration the number of tablets or capsules taken in at the same time should not exceed two.

25 Nevertheless, it may in some cases be advantageous to deviate from the amounts specified, depending on body weight, individual behavior toward the active ingredient, type of preparation and time or interval over which the administration is effected. For instance, less than the aforementioned minimum amounts may be sufficient in some cases, while the upper limit specified has to be exceeded in other cases. In the case of administration of relatively large amounts, it may be advisable to divide these into several individual doses over the day.

30 The combination can comprise effective amounts of at least one compound of Formula I and at least one other therapeutic agent mentioned above, which achieves a greater therapeutic efficacy than when either compound is used alone. The combination can be useful to treat, prevent or manage pulmonary hypertension, where the therapeutic effect is not observed when the agents are used alone, or where an enhanced effect is observed when the combination is administered.

The relative ratios of each compound in the combination can also be selected based on their respective mechanisms of action and the disease biology. The relative ratios of each compound can vary widely and this invention includes combinations for treating, preventing or managing pulmonary hypertension where the amounts of the formula I compound and the other therapeutic agent can be adjusted routinely such that either is present in higher amounts.

The release of one or more agents of the combination can also be controlled, where appropriate, to provide the desired therapeutic activity when in a single dosage form, combination pack, kit or when in separate independent dosage forms.

Preference is given to a combination comprising at least one compound of formula I and at least one compound selected from the group consisting of phosphodiesterase V inhibitors, endothelin antagonists, prostacyclin analogues, kinase inhibitors and elastase inhibitors. More preferably a combination comprising 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-phenoxy}-pyridine-2-carboxylic acid methyl amide (BAY 43-9006) or the *p*-toluenesulfonic acid salt of 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-phenoxy}-pyridine-2-carboxylic acid methyl amide and at least one compound selected from the group consisting of tadalafil, sildenafil, vardenafil, bosentan, sitaxentan, ilomedin, treprostинil and epoprostenol is used. Most preferably a combination comprising 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-phenoxy}-pyridine-2-carboxylic acid methyl amide (BAY 43-9006) or the *p*-toluenesulfonic acid salt of 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-phenoxy}-pyridine-2-carboxylic acid methyl amide and bosentan or vardenafil is used.

**Examples:**

The effects of the compounds and drug combinations according to the invention are tested in vitro on isolated rat pulmonary arteries and in vivo in monocrotaline-treated rats with pulmonary hypertension.

5    **Isolated small pulmonary arteries**

Male Wistar rats (250-300 g) are anaesthetized with ether, and the lungs are removed. The left pulmonary arterial vessel is dissected and placed in ice-cold Krebs-Henseleit (KH) buffer of following composition (in mmol/l): NaCl 112, KCl 5.9, CaCl<sub>2</sub> 2.0 MgCl<sub>2</sub> 1.2, NaH<sub>2</sub>PO<sub>4</sub> 1.2, NaHCO<sub>3</sub> 25, glucose 11.5 and optionally the compound/combination to be tested in a concentration of 10<sup>-10</sup> to 10<sup>-4</sup> mol/l.

For measurement of isometric tension, ring segments, 2 mm in length, are mounted in a small vessel chamber myograph. Two wires (40 µm diameter) are introduced through the lumen of the segments and mounted according to the method described by Mulvany and Halpern (Circulation Research 1977; 41:19-26). After a 30 min equilibration period in oxygenated KH solution at 37 °C and pH = 7.4, segments are stretched to their optimal lumen diameter for active tension development which is determined based on the internal circumference-wall tension ratio of the segments by setting their internal circumference to 90% of what the vessels would have if they are exposed to a passive tension equivalent to that produced by a transmural pressure of 30 mmHg.

Afterwards, segments are washed three times with KH solution and left to equilibrate for 30 min.

20    Segment contractility is then tested by an initial exposure to a high K<sup>+</sup> solution (120 mmol/l K<sup>+</sup>-KH solution, which is identical to KH solution except that NaCl is replaced by KCl on an equimolar basis).

25    The vessels are then pre-contracted using K<sup>+</sup> (50 mmol/l) KH solution. When the contraction is stabilized, an accumulative dose response curve of the compound/combination tested is constructed. The stabilized contraction induced by K<sup>+</sup> (50 mmol/l) KH solution is defined as 100% tension. The relaxation is expressed as percentage tension.

**Pulmonary Artery Pressure in Monocrotaline treated rats**

Male Sprague Dawley rats (250-300g) are treated with monocrotaline 60mg/kg subcutaneously (=day 0). On day 14 after monocrotaline injection treatment the compound/combination to be tested is administered. On day 28 hemodynamic parameters, i.e. right ventricular pressure, systemic

blood pressure, heart rate, arterial and venous oxygen saturation are measured and compared with untreated control animals.

*Results:*

The mentioned monocrotaline (MCT) treated rats are randomized to receive the *p*-toluenesulfonic acid salt of 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-phenoxy}-pyridine-2-carboxylic acid methyl amide 10 mg/kg or vehicle by gavage once daily after the onset of moderate pulmonary arterial hypertension starting 14 days after the injection of MCT until the final hemodynamic measurement on day 28. In animals with MCT-Induced pulmonary arterial hypertension treatment with the *p*-toluenesulfonic acid salt of 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-phenoxy}-pyridine-2-carboxylic acid methyl amide markedly decreases right ventricular systolic pressure, compared to vehicle treated animals (control: 25 ± 0,56 mmHg; *p*-toluenesulfonic acid salt of 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-phenoxy}-pyridine-2-carboxylic acid methyl amide: 36,50 ± 1,50 mmHg vs. placebo: 71,02 ± 5,38 mmHg) (mean ± SEM). This effect of the *p*-toluenesulfonic acid salt of 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-phenoxy}-pyridine-2-carboxylic acid methyl amide is paralleled by a complete inhibition of right ventricular hypertrophy (right ventricle/left ventricle +septum ratio control: 0,26 ± 0,01; the *p*-toluenesulfonic acid salt of 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-phenoxy}-pyridine-2-carboxylic acid methyl amide: 0,26 ± 0,01 vs. placebo: 0,54 ± 0,04).

**Example 1: Immediate release tablet and optionally subsequent film-coating****1.1 Composition of tablets containing the *p*-toluenesulfonic acid salt of 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-phenoxy}-pyridine-2-carboxylic acid methyl amide**

Composition [mg/tablet]	Tablet A 50 mg	Tablet B 200 mg	Tablet C 200 mg	Tablet D 400 mg
<b>Tablet core:</b>	step a), b)	step a), b), c) ii	Step a), b) c) i	Step a), b) c) i
Tosylate salt of compound (I) micronized	68.5 mg	274.0 mg	274.0 mg	548.0 mg
Microcrystalline cellulose	4.0 mg	16.0 mg	16.0 mg	32.0 mg
Croscarmellose sodium	9.1 mg	36.4 mg	36.4 mg	72.8 mg
Hypromellose (5 cP)	2.55 mg	10.2 mg	10.2 mg	20.4 mg
Magnesium stearate	0.425 mg	1.7 mg	2.55 mg <sup>#1</sup> (1.70 - 2.55 mg)	5.10 mg
Sodium lauryl sulfate	0.425 mg	1.7 mg	1.7 mg	3.4 mg
<b>Weight</b>	<b>85.0 mg</b>	<b>340.0 mg</b>	<b>340.85 mg</b> (340.0 - 340.85 mg)	<b>681.70 mg</b>
<b>Film-coating:</b>				
Opadry Red YS2-15531 <sup>#3</sup>	----	10.0 mg	----	----
Hypromellose (15 cP)	----	----	6.00 mg (4.8 - 7.2 mg)	9.0 mg (7.2-10.8 mg)
Macrogol 3350	----	----	2.00 mg (1.6 - 2.4 mg)	3.0 mg (2.4-3.6 mg)
(polyethylene glycol)				
Titanium dioxide	----	----	1.73 mg (1.384 - 2.076 mg)	1.6 mg (1.28-1.92 mg)
Ferric oxide (red)	----	----	0.27 mg (0.216 - 0.324 mg)	----
Ferric oxide (yellow)	----	----	----	1.4 mg (1.12-1.68 mg)
<b>Weight of film coat</b>	<b>----</b>	<b>10.0 mg</b>	<b>10.0 mg</b> (8.0 - 12.0 mg)	<b>15.0 mg</b> (12.0 - 18.0 mg)
<b>Total tablet weight</b>	<b>85.0 mg</b>	<b>350.0 mg</b>	<b>350.85 mg</b> (348 - 352.85 mg)	<b>696.7 mg</b> (348.0-352.85 mg)
<b>Tablet format</b>	<b>Round</b>	<b>round</b>	<b>round</b>	<b>oval</b>
<b>Dimensions of the tablet</b>	<b>diameter: 6 mm</b> <b>diameter: 10 mm</b> , <b>diameter: 10 mm</b> , <b>length: 18 mm</b> , <b>height: 4.5 (±0.3) mm</b> <b>height: 4.5 (±0.3) mm</b> <b>width: 8 mm</b> <b>mm</b>			

<sup>#1</sup> Range for Mg stearate may apply according to manufacturing conditions

<sup>#2</sup> Range for film coat may apply according to manufacturing conditions Fixed ratio of coating components 60 % (hypromellose) - 20 % (polyethylene glycol) - 17.3 % (titanium dioxide) - 2.7 % ferric oxide

<sup>#3</sup> Opadry Red YS-15531 ready to use commercial coating system.

## 10 1.2 Process for manufacturing

### Step a) Granulation

4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-phenoxy}-pyridine-2-carboxylic acid methyl amide micronized, microcrystalline cellulose, croscarmellose sodium, and hypromellose are mixed for 2 minutes in a high shear mixer in order to obtain a powder blend. Sodium lauryl sulfate is

dissolved in water. The powder blend is granulated with the solution in a wet granulation process using a high-shear mixer. The granulation process is finished when the granulate achieves a „snow ball like consistency“. The wet granulation mass is sized using a 4 mm rasp and then dried in a fluidized bed dryer at an inlet air temperature of 80 - 100 °C until a residual moisture of 0.3 up to 5 0.7% by weight (loss on drying) is reached. The dry granules are sieved using a 2 mm sieve size.

Step b) Tablet compression

The granulate is blended with magnesium stearate and croscarmellose sodium using a tumbler blender for from 5 to 10 minutes. The blend is subdivided into single units and compressed to tablets using a standard rotary tablet press at typical tabletting speeds of from 25,000 to 250,000

10 tablets / hour.

Step c) Film-coating

Alternative i:

Hypromellose, polyethylene glycol (Macrogol), titanium dioxide and ferric oxide red are combined with purified water to result in a homogenous coating suspension which is sprayed on the tablets in 15 a perforated drum coater.


Alternative ii:

The commercially available Opadry Red YS-15531 is combined with purified water to result in a homogenous coating suspension which is sprayed on the tablets in a perforated drum coater.

**What we claim:**

1. Use of a compound of formula I or a pharmaceutically acceptable salt, polymorph, solvate, hydrate, metabolite, prodrug or diastereoisomeric form thereof, for manufacture of a medicament for treating, preventing or managing of pulmonary hypertension,

5 wherein said compound of formula I is:



(I)

wherein

Q is  $-\text{C}(\text{O})\text{R}_x$

10  $\text{R}_x$  is hydroxy,  $\text{C}_{1-4}$  alkyl,  $\text{C}_{1-4}$  alkoxy or  $\text{NR}_a\text{R}_b$ ,

$\text{R}_a$  and  $\text{R}_b$  are independently :

a) hydrogen;

b)  $\text{C}_{1-4}$  alkyl, optionally substituted by

-hydroxy,

- $\text{C}_{1-4}$  alkoxy,

15 - a heteroaryl group selected from pyrrole, furan, thiophene, imidazole, pyrazole, thiazole, oxazole, isoxazole, isothiazole, triazole, tetrazole, thiadiazole, oxadiazole, pyridine, pyrimidine, pyridazine, pyrazine, triazine, benzoxazole, isoquinoline, quinolines and imidazopyrimidine


20 - a heterocyclic group selected from tetrahydropyran, tetrahydrofuran, 1,3-dioxolane, 1,4-dioxane, morpholine, thiomorpholine, piperazine, piperidine, piperidone, tetrahydropyrimidone, pentamethylene sulfide, tetramethylene sulfide, dihydropyran, dihydrofuran, and dihydrothiophene,

- amino,  $-\text{NH}_2$ , optionally substituted by one or two  $\text{C}_{1-4}$  alkyl groups, or

- 30 -


- phenyl,
- c) phenyl optionally substituted with
  - halogen, or
  - amino,-NH<sub>2</sub>, optionally substituted by one or two C<sub>1-4</sub> alkyl, or
- 5 d) - a heteroaryl group selected from pyrrole, furan, thiophene,imidazole, pyrazole, thiazole, oxazole, isoxazole, isothiazole, triazole, tetrazole, thiadiazole, oxadiazole, pyridine, pyrimidine, pyridazine, pyrazine, triazine, benzoxazole, isoquiline, quinoline and imidazopyrimidine;

A is an optionally substituted phenyl group of formula 1xx:




10

an optionally substituted pyridinyl group of formula 1x:




or an optionally substituted naphthyl moiety of formula 1y:



15

B is optionally substituted phenyl or naphthyl of formulas 2a and 2b:

- 31 -



L is a bridging group which is -S- or -O-,

p is 0, 1, 2, 3, or 4,

n is 0, 1, 2, 3, 4, 5 or 6,

5 m is 0,1,2 or 3,

each R<sup>1</sup> is independently: halogen, C<sub>1-5</sub> haloalkyl, NO<sub>2</sub>, C(O)NR<sup>4</sup>R<sup>5</sup>, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> dialkylamine, C<sub>1-3</sub> alkylamine, CN, amino, hydroxy or C<sub>1-3</sub> alkoxy.

each R<sup>2</sup> is independently: C<sub>1-5</sub> alkyl, C<sub>1-5</sub> haloalkyl, C<sub>1-3</sub> alkoxy, N-oxo or N-hydroxy,


each R<sup>3</sup> is independently: halogen, R<sup>4</sup>, OR<sup>4</sup>, S(O)R<sup>4</sup>, C(O)R<sup>4</sup>, C(O)NR<sup>4</sup>R<sup>5</sup>, oxo, 10 cyano or nitro (NO<sub>2</sub>) and


R<sup>4</sup> and R<sup>5</sup> are independently hydrogen, C<sub>1-6</sub> alkyl, or up to per-halogenated C<sub>1-6</sub> alkyl.

2. The use of claim 1 wherein

A is 3-tert butyl phenyl, 5-tert butyl-2-methoxyphenyl, 5-(trifluoromethyl)-2 phenyl, 3-(trifluoromethyl) -4 chlorophenyl, 3-(trifluoromethyl)-4-bromophenyl or 5-(trifluoromethyl)-4-chloro-2 methoxyphenyl ;

15 B is






R<sup>1</sup> is fluorine, chlorine, bromine, methyl, NO<sub>2</sub>, C(O)NH<sub>2</sub>, methoxy, SCH<sub>3</sub>, trifluoromethyl, or methanesulfonyl;

R<sup>2</sup> is methyl, ethyl, propyl, oxygen, or cyano and

R<sup>3</sup> is trifluoromethyl, methyl, ethyl, propyl, butyl, isopropyl, tert-butyl, chlorine, fluorine, bromine, cyano, methoxy, acetyl, trifluoromethanesulfonyl, trifluoromethoxy, or trifluoromethylthio.


3. The use of any of claims 1 to 2 wherein the compound of formula I is also of formula II below or salts, polymorphs, solvates, hydrates, metabolites, prodrugs or diastereoisomeric forms thereof:




wherein

Ra and Rb are independently hydrogen and C<sub>1</sub>-C<sub>4</sub> alkyl,

15 B of formula II is




wherein the urea group,  $-\text{NH}-\text{C}(\text{O})-\text{NH}-$ , and the oxygen bridging group are not bound to contiguous ring carbons of B, but rather have 1 or 2 ring carbons separating them, and



5 A of formula (II) is

or




- 34 -

wherein the variable n is 0, 1, 2, 3 or 4, and

$R^3$  is trifluoromethyl, methyl, ethyl, propyl, butyl, isopropyl, tert-butyl, chlorine, fluorine, bromine, cyano, methoxy, acetyl, trifluoromethanesulfonyl, trifluoromethoxy, or trifluoromethylthio.

5 4. The use of any of claims 1 to 3 wherein, each  $R^3$  substituent is chlorine, trifluoromethyl, tert-butyl or methoxy,


A of formula II is



and

10 B of formula II is phenylene, fluoro substituted phenylene or difluoro substituted phenylene.


5. The use of any of claims 1 to 4 wherein the compound of formula I is also of formula X below or salts, polymorphs, solvates, hydrates, metabolites, prodrugs or diastereoisomeric forms thereof:




15

wherein phenyl ring "B" optionally has one halogen substituent,


A is an optionally substituted phenyl group of formula 1xx:



an optionally substituted pyridinyl group of formula 1x:



or an optionally substituted naphthyl moiety of formula 1y:



5

n is 0, 1, 2, 3, 4, 5 or 6,

m is 0,1,2 or 3,

each R<sup>2</sup> is independently: C<sub>1-5</sub> alkyl, C<sub>1-5</sub> haloalkyl, C<sub>1-3</sub> alkoxy, N-oxo or N-hydroxy,


each R<sup>3</sup> is independently: halogen, R<sup>4</sup>, OR<sup>4</sup>, S(O)R<sup>4</sup>, C(O)R<sup>4</sup>, C(O)NR<sup>4</sup>R<sup>5</sup>, oxo, cyano or nitro (NO<sub>2</sub>) and

10

R<sup>4</sup> and R<sup>5</sup> are independently hydrogen, C<sub>1-6</sub> alkyl, or up to per-halogenated C<sub>1-6</sub> alkyl.


6. The use of claim 5 wherein m is zero and A is substituted phenyl with at least one substituent R<sup>3</sup>.
7. The use of claim 6 wherein R<sup>3</sup> is halogen, trifluoromethyl and/or methoxy.

8. The use of claim 1 wherein the compound of formula I also has the structure of one of formulas Z1 or Z2 below or a salt, polymorph, solvate, hydrate, metabolite, prodrug or diastereoisomeric form thereof:



5

or



9. The use of claim 8 wherein the compound of formula I is the tosylate salt of the compound of formula Z1.

10. Combination comprising at least one compound of formula I as defined in any of claims 1 to 9 and at least one elastase inhibitor and/or one kinase inhibitor.

11. Combination of claim of 10 wherein the kinase inhibitor is glivec.

12. Combination comprising at least one compound of formula I as defined in any of claims 1 to 9 or a combination as defined in any of claims 10 to 11 and at least one therapeutic agent selected from the group consisting of anticoagulants, diuretics, cardiac glycosides, calcium channel blockers, vasodilators, prostacyclin analogues, endothelium antagonists, phosphodiesterase inhibitors, endopeptidase inhibitors, lipid lowering agents, thromboxane inhibitors and other therapeutics known to reduce pulmonary artery pressure.

13. Combination of claim 12 wherein the further therapeutic agent is a phosphodiesterase V inhibitor, endothelin antagonist or prostacyclin analogue.

20 14. Combination of claim 12 wherein the further therapeutic agent is tadalafil, sildenafil, vardenafil, bosentan, sitaxentan, ilomedin, treprostinil and epoprostenol.


15. Use of the combination of any of claims 10 to 14 for manufacture of a medicament for treating, preventing or managing of pulmonary hypertension.

16. Pharmaceutical composition comprising a combination as defined in any of claims 10 to 14.

17. Pharmaceutical composition of claim 16 for the treatment of pulmonary hypertension.

18. A method for treating, preventing or managing pulmonary hypertension in a subject in need thereof comprising administering effective amounts of at least one compound of formula I or a pharmaceutically acceptable salt, polymorph, solvate, hydrate, metabolite, prodrug or diastereoisomeric form thereof

5 wherein said compound of formula I is:



wherein

Q is  $-C(O)R_x$

$R_x$  is hydroxy,  $C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy or  $NR_aR_b$ ,

15  $R_a$  and  $R_b$  are independently :

a) hydrogen;

b)  $C_{1-4}$  alkyl, optionally substituted by

-hydroxy,

$-C_{1-4}$  alkoxy,

20 - a heteroaryl group selected from pyrrole, furan, thiophene, imidazole, pyrazole, thiazole, oxazole, isoxazole, isothiazole, triazole, tetrazole, thiadiazole, oxadiazole, pyridine, pyrimidine, pyridazine, pyrazine, triazine, benzoxazole, isoquinoline, quinolines and imidazopyrimidine

- 38 -

- a heterocyclic group selected from tetrahydropyran, tetrahydrofuran, 1,3-dioxolane, 1,4-dioxane, morpholine, thiomorpholine, piperazine, piperidine, piperidinone, tetrahydropyrimidone, pentamethylene sulfide, tetramethylene sulfide, dihydropyran, dihydrofuran, and dihydrothiophene,

5 - amino,-NH<sub>2</sub>, optionally substituted by one or two C<sub>1-4</sub> alkyl groups, or

- phenyl,


c) phenyl optionally substituted with

- halogen, or


- amino,-NH<sub>2</sub>, optionally substituted by one or two C<sub>1-4</sub> alkyl, or

10 d) - a heteroaryl group selected from pyrrole, furan, thiophene, imidazole, pyrazole, thiazole, oxazole, isoxazole, isothiazole, triazole, tetrazole, thiadiazole, oxadiazole, pyridine, pyrimidine, pyridazine, pyrazine, triazine, benzoxazole, isoquiline, quinoline and imidazopyrimidine;


15 A is an optionally substituted phenyl group of formula 1xx:



an optionally substituted pyridinyl group of formula 1x:




or an optionally substituted naphthyl moiety of formula 1y:



5

B is optionally substituted phenyl or naphthyl of formulas 2a and 2b:



L is a bridging group which is -S- or -O-,

10

p is 0, 1, 2, 3, or 4,

n is 0, 1, 2, 3, 4, 5 or 6,

m is 0, 1, 2 or 3,

each R<sup>1</sup> is independently: halogen, C<sub>1-5</sub> haloalkyl, NO<sub>2</sub>, C(O)NR<sup>4</sup>R<sup>5</sup>, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> dialkylamine, C<sub>1-3</sub> alkylamine, CN, amino, hydroxy or C<sub>1-3</sub> alkoxy.

15

each R<sup>2</sup> is independently: C<sub>1-5</sub> alkyl, C<sub>1-5</sub> haloalkyl, C<sub>1-3</sub> alkoxy, N-oxo or N-hydroxy,

each R<sup>3</sup> is independently: halogen, R<sup>4</sup>, OR<sup>4</sup>, S(O)R<sup>4</sup>, C(O)R<sup>4</sup>, C(O)NR<sup>4</sup>R<sup>5</sup>, oxo, cyano or nitro (NO<sub>2</sub>) and

R<sup>4</sup> and R<sup>5</sup> are independently hydrogen, C<sub>1-6</sub> alkyl, or up to per-halogenated C<sub>1-6</sub> alkyl.

19. The method of claim 18 wherein the compound of formula I is combined with at least one  
5 elastase inhibitor and/or one kinase inhibitor.

20. The method of any of claims 18 to 19 wherein the compound of formula I is additionally  
combined with at least one therapeutic agent selected from the group consisting of  
anticoagulants, diuretics, cardiac glycosides, calcium channel blockers, vasodilators,  
prostacyclin analogues, endothelium antagonists, phosphodiesterase inhibitors, endo-  
10 peptidase inhibitors, lipid lowering agents, thromboxane inhibitors and other therapeutics  
known to reduce pulmonary artery pressure.

# INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2006/010405

**A. CLASSIFICATION OF SUBJECT MATTER**  
INV. A61K31/495 A61P11/00

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, EMBASE, BIOSIS

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2004/113274 A2 (BAYER PHARMACEUTICALS CORP [US]; WILHELM SCOTT [US]; DUMAS JACQUES [US]) 29 December 2004 (2004-12-29) page 19, lines 25-27; example B -----	1-20
A	WO 03/068228 A (BAYER AG [US]; DUMAS JACQUES [US]; SCOTT WILLIAM J [US]; ELTING JAMES) 21 August 2003 (2003-08-21) page 27, line 17; example B -----	1-20



Further documents are listed in the continuation of Box C.



See patent family annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
24 January 2007	30/01/2007
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer  Cattell, James

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2006/010405

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
WO 2004113274	A2	29-12-2004	CA	2526617 A1	29-12-2004
			CA	2526636 A1	06-01-2005
			EP	1636585 A2	22-03-2006
			EP	1626714 A2	22-02-2006
			JP	2006528986 T	28-12-2006
			MX	PA05012486 A	03-07-2006
			WO	2005000284 A2	06-01-2005
WO 03068228	A	21-08-2003	AU	2003209116 A1	04-09-2003
			CA	2475703 A1	21-08-2003
			EP	1478358 A1	24-11-2004
			JP	2005522448 T	28-07-2005
			MX	PA04007832 A	08-09-2005